Filtyp
The focus of the clinical virology team is to develop and further improve diagnostic tools for detection and quantification of viral infections, including next-generation sequencing approaches in the field of “pandemic preparedness”. Our current work in the field involves many collaborators, the establishment of biobanks and the use of clinical and environmental specimens in our investigations. Du
https://www.virology.lu.se/clinical-virology - 2025-07-25
Vision We want to create a regionally, nationally and internationally well-known center for translational virus research at the highest level where experimental and clinical research meet in synergy. New Virus Centre Ola Forslund, Marianne Jansson, Joakim Esbjörnsson and Patrik Medstrand. Photos taken by: Ingemar Hultqvist, Björn Martinsson, Elin Anderlind and Tove Smeds. Pandemics and alertnes
https://www.virology.lu.se/virology - 2025-07-25
Human papillomavirus (HPV) infections cause 500.000 cases of cervical cancer each year in the world (400 cases in Sweden), and 250.000 deaths (120 cases in Sweden). HPV16 is the most common cancer-associated HPV type. The majority of all HPV16 infections is cleared by the host but a fraction persists that may cause cancer. The full life cycle of HPV16 requires cell proliferation at the early stage
https://www.virology.lu.se/molecular-virology - 2025-07-25
Gemma Atkinson, Lund University Vasili Hauryliuk, Lund University
https://www.virology.lu.se/affiliated - 2025-07-25
Associate Professor Joakim is an Associate professor at the Department of Translational Medicine, Faculty of Medicine PRINCIPAL INVESTIGATOR
https://www.virology.lu.se/pi-joakim-esbjornsson-phd - 2025-07-25
Principal Investigator, Associate Professor in Virology “What would be easy turned out to be difficult. That is one way of summarising over 30 years of efforts to find a vaccine or a cure for HIV, the virus that causes the disease AIDS. It is this scientific challenge that triggers the researcher Joakim Esbjörnsson.” From “Forskarnas Nyheter”(2017) Joakim Esbjörnsson is an Associate senior lecture
https://www.virology.lu.se/systems-virology/joakim-esbjornsson-phd - 2025-07-25
The Covid-19 pandemic has clearly demonstrated how fast viruses can become a significant threat to global health. Through national and international collaboration, we can improve our readiness for future virus outbreaks.Pandemics and alertness | Lund UniversityLinkedIn_Pandemics_and alertness
https://www.virology.lu.se/pandemics-and-alertness - 2025-07-25
The field of tumor virology has provided groundbreaking insights into the causes of human cancer. In my research at Lund University I focus on I) characterization of human papillomavirus (HPV)-associated mechanisms for disease development and II) use of HPV for prevention of disease.Concerning HPV-associated benign tumors as recurrent laryngeal papilloma, we study de-regulated pathways of the loca
https://www.virology.lu.se/tumor-virology - 2025-07-25
Laryngeal Papilloma Interaction between HPV, respiratory bacteria, and a dysfunctional local immune response may promote laryngeal papilloma. Although presence of human papillomavirus (HPV)-vaccines, there are new cases of HPV-diseases. Such a disease is laryngeal papilloma (LP) which is a benign tumor that can persist during life and is considered incurable, manifested by obstruction in the resp
https://www.virology.lu.se/tumor-virology/projects - 2025-07-25
Ola Forslund, PILouise Pedersen, Lab technicianTove Wadenius, Lab technicianYlva Lindroth, PhD student
https://www.virology.lu.se/tumor-virology/tumor-virology-team - 2025-07-25
Principal Investigator, Associate Professor in VirologyOla Forslund is a Senior Lecturer in Tumor Virology and Associate Professor in Virology at the Department of Translational Medicine, Medical Faculty at Lund University. Ola received his Ph.D in 1997 at Lund University, and performed postdoctoral studies at Umeå University and as a visiting research fellow at IMVS in Adelaide. From 2000 he was
https://www.virology.lu.se/tumor-virology/ola-forslund-pi - 2025-07-25
Ola Forslund Ola Forslund_LUCRISOla Forslund_PubMed
https://www.virology.lu.se/tumor-virology/publications - 2025-07-25
Stefan Schwartz UUMagnus Pålsson, LUAastha SobtiYlva LindrothCaroline HellstenSelamawit Mekuria
https://www.virology.lu.se/tumor-virology/collaborators - 2025-07-25
Associate Professor Ola Forslund, Ph.D.Department of Translational MedicineLund UniversitySölvegatan 23B221 85 Lund, SwedenPhone +46 46-17 19 08Mobile +46 70 33 26 950E-mail: ola [dot] forslund [at] med [dot] lu [dot] se (Ola[dot]forslund[at]med[dot]lu[dot]se)
https://www.virology.lu.se/tumor-virology/contact - 2025-07-25
Joakim Esbjörnsson Joakim Esbjörnsson_LUCRISJoakim Esbjörnsson_PubMedReview articles and invited publications in peer-reviewed international journals Esbjörnsson J, Jansson M, Jespersen S, Månsson F, Hønge BL, Lindman J, Medina C, da Silva ZJ, Norrgren H, Medstrand P, Rowland-Jones SL, Wejse C. HIV-2 as a model to identify a functional HIV cure. AIDS Res Ther. 2019 Sep 5;16(1):24. doi: 10.1186/s12
https://www.virology.lu.se/systems-virology/publications - 2025-07-25
There are two types of HIV, HIV-1 and HIV-2, which can lead to AIDS. HIV-1, with global spread, is the more aggressive and infectious virus. The reason for the difference in pathogenesis between HIV-1 and HIV-2 is not yet clear, and neither is the inhibiting effect that HIV-2 has on HIV-1 in dually infected understood. Our research is focused on understanding the interactions between the immune sy
https://www.virology.lu.se/hiv-host-interactions - 2025-07-25
National Cecilia Ahlström-Emanuelsson - Ear, Nose and Throat Diseases, Lund University Jan Albert - Department of Microbiology, Tumor and Cell Biology, Karolinska Institute Anna Karin Pereira Bastos - Ear, Nose and Throat Diseases, Trelleborg Hospital Per Björkman - Clinical infection medicine, Lund University Stefan Freccero - Ear, Nose and Throat Diseases, Trelleborg Hospital Marianne Jansson -
https://www.virology.lu.se/systems-virology/collaborators - 2025-07-25
Joakim Esbjörnsson, PhDAssociate Professor in VirologySenior Lecturer in Medical MicrobiologyHead of Systems Virology GroupDepartment of Translational MedicineFaculty of MedicineLund UniversityPostal address:Lund UniversityBMC, B13221 84 LundSwedenPhone: +46 46 22 20119, Officeemail: joakim [dot] esbjornsson [at] med [dot] lu [dot] se Honorary Visisting Research Fellow Nuffield Department of Med
https://www.virology.lu.se/contact - 2025-07-25
TEDDY studien samlar in information 40–50 gånger fram till 15 års ålder beroende på om forskningspersonen har autoantikroppar eller ej.Det är information av olika typ som samlas in. Vid varje besök analyseras sju olika autoantikroppar, som är biomarkörer för autoimmun (typ 1) diabetes, celiaki och sköldkörtelinflammation. IAA, GADA, IA-2A och ZnT8A är biomarkörer för autoimmun (typ 1) diabetes. tT
Forskningsartiklar om infektioner hos mamma eller barn Påverkar gastroenterit risken att utveckla insulinautoantikroppar? 2023Ökar svampinfektioner risken för autoantikroppar hos barnen i TEDDY studien? 2022Hur kan virus trigga autoimmun (typ 1) diabetes? 2019Samband mellan amning och infektioner 2019Påverkar infektioner under graviditeten barnets risk att få en första autoantikropp? 2017Hur hante
https://www.teddy.lu.se/resultat-fran-teddy/alla-forskningsartiklar/infektioner - 2025-07-25
